Previous Article | Next Article 
Molecular and Cellular Biology, November 2001, p. 7862-7871, Vol. 21, No. 22
0270-7306/01/$04.00+0 DOI: 10.1128/MCB.21.22.7862-7871.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
CRM1 Mediates the Export of ADAR1 through a Nuclear
Export Signal within the Z-DNA Binding Domain
Hanne
Poulsen,
Jakob
Nilsson,
Christian K.
Damgaard,
Jan
Egebjerg, and
Jørgen
Kjems*
Department of Molecular and Structural
Biology, University of Aarhus, DK-8000 Århus C, Denmark
Received 12 March 2001/Returned for modification 10 July
2001/Accepted 21 August 2001
 |
ABSTRACT |
RNA editing of specific residues by adenosine deamination is a
nuclear process catalyzed by adenosine deaminases acting on RNA (ADAR).
Different promoters in the ADAR1 gene give rise to two
forms of the protein: a constitutive promoter expresses a transcript
encoding (c)ADAR1, and an interferon-induced promoter expresses a
transcript encoding an N-terminally extended form, (i)ADAR1. Here we
show that (c)ADAR1 is primarily nuclear whereas (i)ADAR1 encompasses a
functional nuclear export signal in the N-terminal part and is a
nucleocytoplasmic shuttle protein. Mutation of the nuclear export
signal or treatment with the CRM1-specific drug leptomycin B induces
nuclear accumulation of (i)ADAR1 fused to the green fluorescent protein
and increases the nuclear editing activity. In concurrence, CRM1 and
RanGTP interact specifically with the (i)ADAR1 nuclear export signal to
form a tripartite export complex in vitro. Furthermore, our data imply
that nuclear import of (i)ADAR1 is mediated by at least two nuclear
localization sequences. These results suggest that the nuclear editing
activity of (i)ADAR1 is modulated by nuclear export.
 |
INTRODUCTION |
Adenosine deaminase acting on RNA
(ADAR) deaminates adenosines to produce inosines within RNAs that are
predominantly double stranded. Since inosine has base-pairing
properties similar to those of guanosine, adenosine deamination can
change the coding properties of an mRNA and alter the functional role
of a gene product, a process known as RNA editing (reviewed in
reference 2). The double-stranded RNA (dsRNA) structures
of known in vivo ADAR editing substrates are formed through base
pairing between an exon and an intron in cis, which has led
to the conclusion that editing is a nuclear process preceding splicing
(6, 11, 21, 38, 52). Modulation of the properties of
neuronal receptors and ion channels by adenosine deaminations at
specific sites in the transcripts of, e.g., mammalian glutamate and
serotonin receptors has been described (6, 32),
Drosophila sodium, calcium, and chloride channels (18,
55, 57), and a squid K+ channel (49).
ADAR proteins belong to a multigene family, and three of the mammalian
members, ADAR1, ADAR2, and ADAR3, constitute a structurally related
subfamily (reviewed in reference 29). Cell transfection experiments, genetic knockout of the ADAR genes in mice, and in vitro
studies indicate that ADAR1 and -2 are the deaminases responsible for
the observed editing events (8, 20, 23, 31, 34, 39, 45, 46,
60).
The editing substrates are mostly found in the brain, but the two
deaminases are also expressed in other tissues, which suggests that
there are still unidentified ADAR substrates (59). In
accordance with this, heterozygosity for a null allele of
ADAR1 disturbs the hematopoietic erythropoiesis and is
embryonically lethal in mice (60).
ADAR1, -2, and -3 share a very similar overall domain structure.
Functional domains include two or three repeats of a 70-amino-acid dsRNA binding motif followed by a highly conserved catalytic domain near the C terminus (8, 31, 41). Unique to the
ADAR1 gene locus is the presence of both constitutive and
interferon-induced promoters that produce transcripts with different
first exons (15). The interferon-induced mRNA encodes the
form (i)ADAR1, which is extended by 295 amino acids at the N terminus
compared to the constitutively expressed form, (c)ADAR1. There is a
basal expression of both forms of the protein (31, 48,
60), but treatment with alpha, beta, or gamma interferon
increases the level of (i)ADAR1 mRNA two- to threefold
(9). The in vitro deamination activities of (c)ADAR1 and
(i)ADAR1 are similar. Both enzymes are capable of site-specific editing
of pre-mRNA substrates (35, 37) as well as more unspecific
deamination of up to half of the adenosines in extended,
perfectly double-stranded RNA (36), suggesting that
the substrate recognition and catalytic domains are fully retained
within (c)ADAR1. The (i)ADAR1 N-terminal extension encompasses a
65-amino-acid domain, Z
, that can bind both DNA and dsRNA in a Z
conformation (5, 19). Nuclear magnetic resonance (NMR) and
crystal structures of the Z
domain reveal a helix-loop-helix structure similar to that found in many B-DNA binding proteins (53, 54). The functional significance of Z
is still
unknown, but the domain has been suggested to direct (i)ADAR1
either to newly synthesized transcripts in the nucleus via binding of
Z-DNA formed at transcription or to cytoplasmic viral dsRNA substrates (5, 19).
The nuclear pore complex (NPC) which spans the nuclear membrane
generally allows free diffusion of proteins smaller than 40 to 60 kDa,
while the translocation of larger proteins or protein complexes is
controlled by nuclear localization signals (NLSs) and nuclear export
signals (NESs). These elements are recognized by soluble import and
export receptors, which can associate with nucleoporins in the NPC,
thus leading to transport of cargo across the membrane (reviewed in
references 16 and 40).
The classic NLS motif present in most nuclear proteins is composed of
one or two clusters of basic residues, and it is recognized by the NLS
receptor importin
, which attaches the cargo to the NPC through the
import factor importin
. By a largely unknown mechanism, the cargo
is translocated through the NPC, and in the nucleus, an interaction
between importin
and the small GTPase Ran leads to dissociation of
the complex (17, 50, 61). The most common NES motif in
proteins is a stretch of characteristically spaced hydrophobic amino
acids as first described for the human immunodeficiency virus type 1 Rev and PKI proteins (12, 62). In the nucleus, this motif
is recognized by the nuclear export receptor CRM1, which forms a
competent nuclear export complex together with RanGTP (13, 14,
47, 58). After translocation through the NPC, cytoplasmic
factors, including Ran GTPase activating protein (RanGAP) and Ran
binding proteins 1 and 2, promote hydrolysis of Ran-bound GTP and the
cargo is released (1, 28).
In accordance with RNA editing preceding splicing, the deamination
activity of somatic cells is nuclear (59, 64), and both
ADAR2 and (c)ADAR1 have been demonstrated to localize to the nucleus
(30, 46, 48). Two putative ADAR1 NLSs have been suggested,
one in the Z
domain and one in the N terminus of (c)ADAR1 (22), but despite the suggested NLSs, a fraction of
(i)ADAR1 localizes to the cytoplasm (48). These
observations prompted us to search for a putative NES in (i)ADAR1, and
in this study, we characterized a functional Rev-like NES in the
N-terminal part of (i)ADAR1. Via the NES and at least two NLSs,
(i)ADAR1 can shuttle between the nucleus and the cytoplasm.
 |
MATERIALS AND METHODS |
Plasmid constructs.
The open reading frame of full-length
human ADAR1 (splice version a) cloned into the XhoI
and XbaI restriction sites of pBluescript II KS(+)
(Stratagene) was a kind gift from André Gerber and Walter Keller
(46). The open reading frame was subcloned into pcDNA3 (Invitrogen) using the same restriction sites. Insertion of different fragments of this plasmid into the pEGFP C1 vector (Clontech) yielded
four constructs with enhanced green fluorescent protein (EGFP) fused in
frame to the N terminus of the ADAR1 fragments. The
EcoRV-ApaI fragment of (i)ADAR1 inserted into the
Ecl136II and ApaI sites of the vector generates a
fusion protein with the full-length (i)ADAR1 sequence
[EGFP-(i)ADAR1]. The EcoRV-BamHI and the
BamHI-ApaI fragments of (i)ADAR1 inserted into
the Ecl136II-BamHI and
BglII-ApaI sites of the vector, respectively,
generate proteins with EGFP fused to the 269 N-terminal amino acids
(EGFP-N-term) or the 958 C-terminal amino acids of (i)ADAR1
(EGFP-C-term), respectively. The Escherichia coli
expression plasmids were generated by digesting the PCR product from
primers 5' ACT GGA TCC ATG AAT CCG CGG CAG GG 3' and 5'
ACT GAA TTC CTA GTC TAA AAA CTC AAG AGG 3' on full-length (i)ADAR1 with BamHI and EcoRI and inserting the
fragment into the equivalent sites in the pGEX-GTH vector, yielding the
(i)ADAR1 1-295 sequence with an N-terminal glutathione
S-transferase (GST) tag [pGEX-GTH-(i)ADAR1(1-295)].
Mutagenesis of the NES (L133A/I135A double mutation, referred to as
NESmut herein) was achieved by a modified version of the
megaprimer method (27). The N-terminal fragment was also
subcloned into pET vectors for in vitro translation. An3-NESmut, encoding An3 with mutations in the NES, has
been described elsewhere (1). The editing construct R2L,
kindly provided by Trine E. Larsen, contains the sequence from exon 13 to exon 16 of rat GluR2 inserted into pcDNA3 (T. E. Larsen and J. Egebjerg, unpublished results).
Cell cultures.
The mouse neuroblastoma cell line N2A and the
human fibrosarcoma cell line HT1080 were cultured at 37°C and 7.5%
CO2 in Dulbecco's modified Eagle medium containing 5 and
10% fetal calf serum, respectively. Lipofectamine (Life Technologies)
was used for transient transfections according to the manufacturer's
instructions. Leptomycin B (LMB), a generous gift from Minoru Yoshida,
was added to the medium to a final concentration of 2 nM.
Localization of endogenous (i)ADAR1.
HT1080 cells were
seeded in 100-mm dishes, LMB was added 24 h later, and after
another 6 h, the cells were harvested with 2 mM EDTA in
phosphate-buffered saline (PBS) and washed. Cells were lysed for 5 min
on ice in buffer L (0.5% NP-40 in PBS with protease inhibitors).
Nuclei were sedimented at 4,500 × g through a sucrose
cushion (24% sucrose-1% NP-40 in PBS) in a swing-out bucket rotor
and resuspended in buffer L. The nuclei were extracted with a glass
homogenizer (Douncer; Wheaton) and incubated with 200 U of
Benzoase (Roche) at 0°C overnight. Nuclear and cytoplasmic fractions
were resolved on a sodium dodecyl sulfate (SDS)-6%
polyacrylamide gel, and Western blotting was performed with a primary
polyclonal antibody against human ADAR1. Bands were visualized by
standard techniques using a secondary antibody and enhanced
chemiluminescence (Pharmacia Biotech). Gels run in parallel were
stained with Coomassie blue to ensure equal loading, and to verify the
separation of nuclear and cytoplasmic fractions, Western blots were
stripped and reprobed with antibodies against topoisomerase type I
(Genosys Biotechnologies Inc.) and the eukaryotic release factor 3a,
which are constitutively nuclear and cytoplasmic proteins, respectively.
Oocyte injections.
Microinjection of proteins into oocytes,
incubations, and extractions were performed as described previously
(1). In vitro translations were done with the TNT coupled
reticulocyte lysate system (Promega) according to the manufacturer's
instructions. Proteins were dialyzed into PBS with 8.7% glycerol.
Protein expression.
pGEX-GTH-(i)ADAR1(1-295) and
pGEX-GTH- (i)ADAR1(1-295)NESmut were expressed in the
E. coli strain BL21(DE3), yielding the proteins
GST-(i)ADAR1(1-295) and GST-(i)ADAR1(1-295)NESmut.
Bacterial cultures were induced in early log phase with 1 mM IPTG
(isopropyl-
-D-thiogalactopyranoside) for 3 h at
37°C. Bacteria recovered by centrifugation were resuspended in buffer
A (300 mM NaCl, 50 mM Tris-HCl [pH 7.5], 5 mM 2-mercaptoethanol, protease inhibitors), lysed by a French press, and cleared by centrifugation. The supernatant was incubated with glutathione agarose
(Pharmacia Biotech) for 1 h at 4°C, followed by washing with
buffer A. The bound proteins were eluted with SG buffer (120 mM NaCl,
100 mM Tris-HCl [pH 8.0], 20 mM glutathione) for 30 min at 4°C. Top
fractions were diluted into 50 mM phosphate (pH 6.6) and purified by
fast protein liquid chromatography on an SP-Sepharose column using a 0 to 1,200 mM NaCl gradient. Finally, the proteins were dialyzed into
storage buffer (150 mM NaCl, 50 mM Tris-HCl [pH 7.5], 1 mM
dithiothreitol [DTT], 10% glycerol) and stored at
80°C. The
purification of His-tagged CRM1, Ran, and Rna1p was performed as
previously described (44).
Hydrolysis assay.
Four nanomolar Ran
[
-32P]GTP (5,000 Ci/mmol; Pharmacia Biotech) was
incubated with 200 nM GST-(i)ADAR1(1-295) or
GST- (i)ADAR1(1-295)NESmut and 0 to 400 nM CRM1
in reaction buffer (40 mM Tris-HCl [pH 8.0], 8 mM MgCl2,
1 mM DTT, 2 mM GTP, 1 mg of BSA per ml). Complex formation on ice was
allowed for 15 min before addition of RanGAP to a final concentration
of 5 nM, followed by incubation for 2 min at 25°C. Reactions were
stopped by adding 1 ml of charcoal suspension (7% [wt/vol] charcoal,
10% [vol/vol] ethanol, 0.1 M HCl, 10 mM
KH2PO4), and the released
-32P
was measured by counting on 0.7 ml of the supernatant.
Coprecipitation assay.
GST-(i)ADAR1(1-295) or
GST-(i)ADAR1(1-295)NESmut (1 µM each) was
incubated with 200 nM CRM1 in either the presence or absence of 4 µM
RanGTP in TB buffer (20 mM HEPES-KOH [pH 7.3], 110 mM potassium
acetate [KOAc], 5 mM NaOAc, 2 mM MgOAc, 1 mM DTT). After 30 min of
incubation on ice, 20 µl of glutathione beads (Pharmacia Biotech) was
added and incubation was continued for 60 min. Unbound protein was
removed, beads were washed with 20 column volumes, and bound proteins
eluted with SDS loading buffer were analyzed by SDS-polyacrylamide gel
electrophoresis (PAGE).
In vivo editing.
The editing construct R2L and various
EGFP-(i)ADAR1-expressing constructs were cotransfected into N2A cells.
Cytoplasmic RNA was purified 2 days after transfection with the RNeasy
kit (Qiagen), and Superscript II reverse transcriptase (RT) (Life
Technologies) was used for reverse transcription of the RNA with a
GluR2 exon 16-specific primer (Ex16; 5' CCG GGA CTT GTA GCA GAA
CTC 3') at 42°C for 40 min followed by 10 min at 45°C. The
cDNA was amplified by PCR using Ex16 and a T7 primer. A PCR product
with a length of 590 bp corresponding to spliced GluR2 RNA was purified
after agarose gel electrophoresis and used to estimate the editing at the R/G site by extension of primer 5' [32P]ACA CCT
AAA GGA TCC TCA TT 3' (radiolabeled using T4 polynucleotide kinase (New England BioLabs) with [
-32P]ATP (3,000 Ci/mmol; Pharmacia Biotech) in the presence of 5 mM ddGTP and 0.5 mM
dATP, dCTP, and dTTP or 5 mM ddATP and 0.5 mM dGTP, dCTP, and dTTP. The
reactions were analyzed by gel electrophoresis on an 18%
polyacrylamide gel, and the intensities of the bands were quantified by
PhosphorImager. Extensions with ddATP showed that the A 5' to the R/G
site was deaminated only if the R/G site was edited; thus, the editing
level at the R/G site was determined as the sum of the signals obtained
from extension of the primer by one nucleotide (both A's deaminated)
and two nucleotides (only the R/G site edited) relative to the sum of
the signals from primers extended by one, two, and three nucleotides
(the latter corresponding to unedited RNA).
The transfection efficiencies were estimated as the fraction of green
fluorescing cells 48 h after transfection by visual inspection. Cells
were lysed, and the amount of total protein loaded was estimated with
the Bio-Rad protein assay (Bio-Rad Laboratories). The lysates were
separated on SDS-6% polyacrylamide gels, and Western blotting
with the ADAR1-specific antibody was performed as described above to
estimate the expression levels of the constructs.
 |
RESULTS |
(i)ADAR1 is exported to the cytoplasm by an LMB-sensitive
pathway.
To investigate the localization of endogenous ADAR1, we
performed SDS-PAGE and Western blotting of nuclear and cytoplasmic fractions of the human fibrosarcoma cell line HT1080 using an antibody
specific for human ADAR1. It confirmed that (c)ADAR1 is a nuclear
protein with only a minor fraction present in the cytoplasm,
while (i)ADAR1 is equally distributed between the nucleus and the
cytoplasm (Fig. 1,
LMB). To determine
whether the observed cytoplasmic localization of (i)ADAR1 is a
consequence of CRM1-mediated nuclear export, we treated the cells with
the fungicide LMB, which binds CRM1 covalently and inhibits its
function (13, 33). The LMB treatment reduced the
cytoplasmic fraction of (i)ADAR1 to less than 10%, whereas (c)ADAR1
resided unaffected in the nucleus independent of LMB treatment (Fig. 1,
+LMB). CRM1 is therefore a likely candidate as the nuclear export
receptor for (i)ADAR1.

View larger version (55K):
[in this window]
[in a new window]
|
FIG. 1.
The localization of endogenous (i)ADAR1 is changed by
LMB treatment. HT1080 cells were incubated for 6 h with or without
LMB as indicated and separated into nuclear (N) and cytoplasmic (C)
fractions. Equivalent amounts of total protein were subjected to
SDS-PAGE and Western blotting with an antibody specific for human ADAR1
and visualized using a secondary antibody, enhanced chemiluminescence,
and fluorography (top panel). Bands corresponding to (c)ADAR1 and
(i)ADAR1 and a size marker are indicated on the right. Part of the
samples were subjected to SDS-PAGE and stained with Coomassie blue to
ensure equal loading (middle panel). The ratio of cytoplasmic (i)ADAR1
to nuclear (i)ADAR1 (C/N) was determined in six parallel experiments,
and the average values and error thresholds are presented in the lower
panel. Nuclear and cytoplasmic fractions were also probed with
antibodies against topoisomerase type I and eukaryotic release factor
3a, representing constitutively nuclear and cytoplasmic proteins,
respectively. This showed that there was no detectable leakage between
the two compartments during the separation procedure and confirmed
equal loading (data not shown).
|
|
A phylogenetically conserved NES-like sequence in
(i)ADAR1.
The difference in distribution of (c)ADAR1 and
(i)ADAR1 is consistent with the existence of a NES in the (i)ADAR1 N
terminus. The RNA-binding and catalytic domains of ADAR1 are highly
conserved among mammals, Xenopus laevis, and fish, while the
N-terminal regions are far more variable (56).
Nonetheless, an examination of the N termini revealed that all ADAR1
species encompass the putative NES motif LXXX
XXLX
(where X
denotes any amino acid and
denotes one of the hydrophobic residues
I, V, F or L) (Fig. 2A) that conforms to
the consensus leucine-rich NES found in several other nucleocytoplasmic
shuttling proteins that utilize CRM1 as their transport receptor (Fig.
2A). An N-terminal NES may therefore be phylogenetically
conserved in (i)ADAR1.

View larger version (27K):
[in this window]
[in a new window]
|
FIG. 2.
(A) Alignment of putative ADAR1 NESs from different
species. The conserved hydrophobic motif, characteristic of a NES
protein exported by the CRM1 pathway, is highlighted in bold. The amino
acid positions are indicated on the left; the 5' end of the
Tetraodon fluviatilis ADAR1 open reading frame has
not been identified. The corresponding GenBank accession numbers are
(from the top): NM 001111.2, U18942.2, AF052506.2, U88065.1, U88066.1,
AF124048.1, AF124332.1, and AF124334.1. (B) Schematic representation of
the functional domains in the EGFP-(i)ADAR1 proteins expressed in
transient transfections and the GST-(i)ADAR1 fusion proteins used for
in vitro binding studies. Numbers denote the amino acid position
relative to the N terminus of human (i)ADAR1 (splice version a)
(46), and the boxes indicate functionally characterized
domains: grey box, Z-DNA binding domain Z ; black boxes, dsRNA
binding domains; hatched box, catalytic domain. The sequence of the
wild-type NES is shown above the EGFP-(i)ADAR1 construct, and the
mutated NES sequence is denoted by a cross and is shown below the
EGFP-N-term-NESmut construct. The mutated amino acids are
underlined.
|
|
Characterization of an N-terminal NES in (i)ADAR1.
To
characterize the ADAR1 localization signals further, we transiently
transfected the mouse neuroblastoma cell line N2A with an expression
plasmid encoding human ADAR1 fused to EGFP at the N terminus
[EGFP-(i)ADAR1] (Fig. 2B) and examined the localization of the fusion
protein by fluorescence microscopy (Fig.
3). The distribution of
nuclear and cytoplasmic EGFP signals is quantitated in Table
1. EGFP-(i)ADAR1 localizes almost
exclusively to the cytoplasm (Fig. 3C; Table 1), whereas EGFP alone
localizes diffusely to both the cytoplasm and to the nucleus, except
for the nucleoli (Fig. 3A).


View larger version (114K):
[in this window]
[in a new window]
|
FIG. 3.
Subcellular localization of ADAR1 proteins. (A to J)
Fluorescence microscope images (Olympus IX70) of living N2A cells were
taken 24 h after transfections with the indicated EGFP-(i)ADAR1
constructs (Fig. 2B). (B, F, G, and H) Cells were treated with 2 nM LMB
for 4 h. (H) Cells were transferred from 37 to 4°C immediately
after the addition of LMB. The nucleocytoplasmic distribution is
quantitated for panels C to J in Table 1. (K) Nuclear export of
GST-(i)ADAR1(1-295) in X. laevis oocytes. X. laevis oocyte nuclei were injected with in vitro-translated
GST-(i)ADAR1(1-295) or GST-(i)ADAR1(1-295)NESMut together
with An3 NESmut protein as a control. Oocytes were
dissected into nuclear (N) and cytoplasmic (C) fractions immediately
(lanes 1, 2, 7, and 8) or after incubation for 90 min (lanes 3, 4, 9, and 10) or 180 min (lanes 5, 6, 11, and 12) and labeled proteins were
visualized by SDS-PAGE and fluorography.
|
|
Like EGFP-(i)ADAR1, EGFP fused to the N-terminal 269 amino acids
(EGFP-N-term) (Fig.
2B) localizes almost exclusively to the
cytoplasm
(Fig.
3E; Table
1), while EGFP fused to the C-terminal
958 amino acids
(EGFP-C-term)(Fig.
2B) is primarily nuclear (Fig.
3D; Table
1). In
agreement with the observations made with endogenous
ADAR1, these
results indicate that (c)ADAR1 harbors a functional
NLS and that
(i)ADAR1 has an N-terminal NES counteracting the
NLS.
To confirm that the cytoplasmic localization is mediated by the
predicted NES, we mutated two of its hydrophobic residues,
L133 and
I135, to alanines in the constructs expressing full-length
(i)ADAR1
[EGFP-(i)ADAR1-NES
mut] (Fig.
2B) and the N-terminal
fragment
(EGFP-N-term-NES
mut) (Fig.
2B). For both
constructs, nuclear localization
was evident in nearly all of the cells
(Fig.
3I and J; Table
1),
while nuclear localization was observed in
<10% of cells transfected
with the wild-type constructs (Fig.
3C and
E; Table
1). Since
mutations in the proposed NES change the
localization of EGFP
fusion proteins from cytoplasmic to nuclear, the
sequence is likely
to direct the nuclear export of
(i)ADAR1.
To determine the nuclear export pathway of the transiently expressed
EGFP-(i)ADAR1, we examined the effect of treating the
transfected cells
with LMB. After 4 h of LMB-treatment, nuclear
accumulation was
evident in nearly all cells transfected with
a construct encoding
either EGFP-(i)ADAR1 or EGFP-N-term (Fig.
3F and G; Table
1), whereas
LMB had no effect on EGFP localization
(Fig.
3B). This implies that the
observed cytoplasmic localization
of (i)ADAR1 is dependent on
functional CRM1 and indicates that
(i)ADAR1 can shuttle between the
nucleus and the
cytoplasm.
The ability of the characterized NES to directly mediate export from
the nucleus was addressed by injecting in vitro-translated
GST-(i)ADAR1(1-295) or GST-(i)ADAR1(1- 295)NES
mut into
the nuclei
of
X. laevis oocytes and dissecting the oocytes
into nuclear and
cytoplasmic fractions at different incubation times
(Fig.
3K).
After 90 min, GST-(i)ADAR1(1-295) had accumulated in the
cytoplasm
(Fig.
3K, lanes 1 to 4), while
GST-(i)ADAR1(1-295)NES
mut remained
exclusively in the
nucleus (Fig.
3K, lanes 7 to 10). Even after
prolonged incubation,
GST-(i)ADAR1(1-295)NES
mut did not show any
export activity
(Fig.
3K, lanes 11 and 12). The An3 protein (
1)
with a
mutated NES served as a negative
control.
The N terminus of (i)ADAR1 is thus able to directly access the CRM1
export
pathway.
In vitro interaction between (i)ADAR1 and CRM1.
To demonstrate
a direct interaction between (i)ADAR1 and CRM1, we tested if the
N-terminal fragment of (i)ADAR1 could form a complex with CRM1 and
RanGTP in vitro. Protein fragments with the N-terminal 295 amino acids
of (i)ADAR1, carrying either wild-type NES or a NES with the L133A and
I135A mutations, were expressed as GST fusion proteins
[GST-(i)ADAR1(1-295) and GST-(i)ADAR1(1-295)NESmut, respectively] (Fig. 2B) in E. coli, and the purified
proteins were incubated with recombinant CRM1 in either the presence or absence of RanGTP. ADAR1 and proteins associated with ADAR1 were precipitated from solution by the addition of glutathione agarose beads, and after washing, bound proteins were eluted and analyzed by
SDS-PAGE (Fig. 4A). In the absence of
RanGTP, only small amounts of CRM1 were retained, but the addition of
RanGTP allowed CRM1 to bind ADAR1 (Fig. 4A, lanes 3 and 4). This
interaction was sensitive to mutations in the ADAR1 NES, as this mutant
only bound residual amounts of CRM1 (Fig. 4A, lanes 1 and 2).

View larger version (34K):
[in this window]
[in a new window]
|
FIG. 4.
In vitro interaction between CRM1 and the (i)ADAR1
NES. (A) Coprecipitation of CRM1 by the N-terminal 295 amino acids of
(i)ADAR1. 1 GST-(i)ADAR1(1-295) or GST-(i)ADAR1(1-295)
NESmut (1 µM) was incubated with 200 nM CRM1 in either
the presence or absence of 4 µM RanGTP. GST-(i)ADAR1 and bound
proteins were precipited by addition of glutathione beads, and, after
washing, bound proteins were resolved by SDS-PAGE. The identities of
the bands are indicated on the left. (B) Binding of a NES to CRM1
occurs in a tripartite complex with RanGTP. The GTPase activity of Ran
is blocked when it is complexed to NES-CRM1 and can therefore be used
as a measure of NES binding (1, 44). This assay was used
to assess the capacity of GST-(i)ADAR1(1-295) (diamonds) and
GST-(i)ADAR1(1-295)NESmut (squares) proteins to form a
tripartite complex. The degree of hydrolysis was measured as the
fraction of released 32P 2 min after the addition of 5 nM RanGAP to 200 nM of the (i)ADAR1 fragments preincubated with 0 to
400 nM CRM1.
|
|
To estimate the
Kd of complex formation, we used
an assay based on the observation that RanGAP-induced GTP hydrolysis by
Ran
is blocked when RanGTP is in complex with CRM1 and a NES substrate
(
1,
4). Ran charged with [
32P]GTP was
incubated with GST-(i)ADAR1(1-295) or
GST-(i)ADAR1(1-295)NES
mut and increasing concentrations of
CRM1. The amount of complexed
RanGTP was measured as the release of

-
32P upon addition of RanGAP, and the level of complex
formation
was determined from this (Fig.
4B). From the 50% hydrolysis,
we
estimate the
Kd between CRM1 and wild-type
(i)ADAR1 NES to be
45 nM, while mutations in the NES lower the binding
substantially
(Fig.
4B). The above results support the idea that CRM1
binds
specifically to the suggested NES in
(i)ADAR1.
NLSs in (i)ADAR1.
The nuclear accumulations of EGFP-N-term in
LMB-treated cells and EGFP-N-term-NESmut (Fig. 3J and G)
suggest the presence of an NLS in the N-terminal fragment.
Alternatively, the expected molecular mass of about 60 kDa (including
the EGFP) may permit diffusion through the NPC, and the protein might
then be retained in the nucleus, e.g., via the Z
domain. To
distinguish between the models, EGFP-N-term was transiently expressed
in N2A cells and transferred to 4°C immediately after the addition of
LMB (Fig. 3H). Receptor-mediated nuclear import and export are
energy-dependent processes that will be blocked by this shift in
temperature, while diffusion is unaffected (42). At the
low temperature, LMB treatment had no effect, and EGFP-N-term remained
cytoplasmic (compare Fig. 3G and H; Table 1), but when the temperature
was raised to 37°C after the 4°C treatment, EGFP-N-term became
nuclear (data not shown). This strongly suggests that an NLS within the
N-terminal 269 amino acids directs active import of the protein.
Moreover, the nuclear localization of the C-terminal ADAR1 fragment
(Fig. 3D), which is too large (>130 kDa) to diffuse across the nuclear membrane, implies that an additional NLS is located in this part of the protein.
RNA editing by ADAR1 is regulated by localization.
Since
site-specific editing by adenosine deamination in all studied cases
precedes splicing, it must occur in the nucleus. One well-studied
example is the most 3' adenosine of the GluR2 exon 13 (the R/G site),
which is differentially edited in the mammalian brain, and in vitro as
well as knockout studies suggest that it is a substrate for both ADAR1
and ADAR2 (34, 38, 60). To determine the nuclear editing
activity of the ADAR1 fusion proteins, we expressed a splicing- and
editing-competent RNA that contained the sequence of GluR2 pre-mRNA
from exon 13 to exon 16 (R2L). N2A cells were transiently cotransfected
with R2L and various EGFP-(i)ADAR1 constructs, and after 48 h
cytoplasmic RNA was purified and amplified by RT-PCR using R2L-specific
primers. The PCR product corresponding to spliced RNA was gel purified, and the editing level at the R/G site was determined by primer extension (Fig. 5).

View larger version (40K):
[in this window]
[in a new window]
|
FIG. 5.
Nuclear RNA editing by ADAR1. N2A cells were
cotransfected with a minimal editing and splicing construct, R2L,
encompassing the R/G site of the rat GluR2 pre-mRNA and expression
plasmids, encoding EGFP-(i)ADAR1 fusion constructs. +LMB, LMB was added
to 2 nM 18 h posttransfection (lanes 5 and 6). At 48 h after
transfection, cytoplasmic RNA was purified and subjected to RT-PCR, and
the editing level at the R/G site was determined by primer extension.
The editing levels were calculated from the sum of the intensities of
the two bands (marked "edited") corresponding to deamination of one
or two adenosines at the R/G site relative to the signal from the band
representing unedited RNA (marked "unedited") (see Materials and
Methods). The signals were quantitated by phosphorimaging, and the
averages and standard deviations of the result from three parallel
experiments are shown.
|
|
The GluR2 construct was edited <5% in cells cotransfected with EGFP
alone or with EGFP fused to (i)ADAR1 (Fig.
5, lanes 1
and 2), while
cotransfection with EGFP-(i)ADAR1-NES
mut raised
the level
to 16% (Fig.
5, lane 3). This indicates that the fusion
proteins are
catalytically active but that the cytoplasmic localization
of
EGFP-(i)ADAR1 abolishes nuclear editing. Removal of the N terminus,
including the NES, in EGFP-C-term further raised the editing level
to
30% (Fig.
5, lane 4). Western blot analysis of transfected
cells
showed that the concentrations of the transiently expressed
ADAR1
proteins were more than 100-fold higher than the concentration
of
endogenous ADAR1, explaining why endogenous (c)ADAR1 edits
the
GluR2 construct to only a very low degree (data not
shown).
To ensure that the NES mutation was not directly responsible for the
change in catalytic activity, we added LMB 18 h after
transfection
with EGFP-(i)ADAR1. The nuclear editing level was
raised to 8% (Fig.
5, lane 6), while the drug had no effect on
the level in
EGFP-transfected cells (Fig.
5, lane 5). This confirms
that
EGFP-(i)ADAR1 is catalytically active if retained in the
nucleus but
exhibits a reduced nuclear editing level because of
its primarily
cytoplasmic
localization.
 |
DISCUSSION |
All known examples of site-specific RNA editing by adenosine
deamination depend on RNA structures formed between exon and intron
segments in the pre-mRNA, and the process has therefore been regarded
as strictly nuclear. However, in this study we have demonstrated that
the interferon-induced form of human ADAR1 is exported from the nucleus
via the NES sequence
LSSHFQELSI (conserved hydrophobic amino acids are in boldface) in the N terminus. The sequence conforms to the consensus leucine-rich-type NES whose export receptor is CRM1. Four lines of evidence suggest that the NES we
have characterized in (i)ADAR1 is functional and that CRM1 is its
cognate export receptor. (i) Treatment of cells with LMB, which
specifically targets CRM1, induces nuclear accumulation of (i)ADAR1
proteins. This was demonstrated for both endogenous (i)ADAR1 and
transiently expressed EGFP-(i)ADAR1. (ii) Mutations in the NES also
result in nuclear accumulation. (iii) In vitro CRM1 binds
specifically to a fragment of (i)ADAR1 containing the wild-type NES in
the presence of RanGTP, and mutations in the NES lower the binding
substantially. (iv) The N terminus of (i)ADAR1 is rapidly exported to
the cytoplasm when injected into the nuclei of X. laevis
oocytes, while mutations in the NES abolish this export.
The number and the spacing of hydrophobic residues in the human
(i)ADAR1 NES described here are conserved in ADAR1 from different organisms, and a study of the ADAR1 localization in X. laevis supports the existence of a functional N-terminal NES.
Full-length ADAR1 in X. laevis localizes mainly to the
cytoplasm, but when approximately 30 kDa of the N terminus, including
the putative NES, are proteolytically removed, the protein becomes
nuclear (10).
The NES that we have characterized overlaps with the N-terminal part of
the Z-DNA binding domain, Z
, which has been studied by NMR and X-ray
crystallography, and in the NMR structure, the entire NES region is
included (53, 54). Caution must be taken when the
structures of protein termini in NMR studies are assigned, but the
suggested (i)ADAR1 NES folds into a
-helix-like structure, which is
similar to what has been described for other putative NESs, including
p53, I
B, the 14-3-3 peptide, Stat 1, and
-actin (3, 24-26,
43, 51). As previously noted by Rittinger et al. for the 14-3-3 peptide (51), the first three hydrophobic residues can
cluster to one side of an aliphatic helix and provide a potential
hydrophobic binding platform for CRM1, whereas the last C-terminal
residue is located at the opposite side of the helix.
Given the size of (c)ADAR1, its nuclear localization must depend on
active import and our transfection experiments with the N-terminal part
of (i)ADAR1 demonstrate an NLS sequence in this region. This is based
on the observation that inhibition of CRM1 leads to nuclear
accumulation of EGFP-N-term at 37°C, but if active import is also
inhibited by lowering the temperature, EGFP-N-term remains in the
cytoplasm. We therefore conclude that (i)ADAR1 is likely to shuttle
between the nucleus and the cytoplasm via a NES and at least two NLSs.
The observation that both EGFP-(i)ADAR1-NESmut and
EGFP-C-term are capable of editing the R/G site raises the
possibility that the N terminus mainly serves to target (i)ADAR1
to different substrates than those of (c)ADAR1 and ADAR2. One
scenario is that nuclear export of (i)ADAR1 is used as a means of
modulating the nuclear deaminase activity. Regulating the activity of a
protein by controlled compartmentalization is a fast mechanism utilized in, e.g., signal transduction and cell cycle regulation (3, 63). Alternatively, (i)ADAR1 may have specific cytoplasmic
targets, such as dsRNA viruses (reviewed in reference 7).
Although further experiments are required to test for such an effect,
this would clearly explain why (i)ADAR1 contains an NES.
 |
ACKNOWLEDGMENTS |
H.P. and J.N. contributed equally to this work.
We thank Marie Öhman, Brenda L. Bass, and Herbert L. Ley III
for the ADAR1-specific antibody, Just Justesen for the eRF3a-specific antibody, André Gerber and Walter Keller for the ADAR1 plasmid, Iain W. Mattaj for the CRM1 plasmid, Dirk Görlich for the Ran and
Rna1p plasmids, Trine E. Larsen for the R2L R/G editing construct, and
Minoru Yoshida for a generous supply of LMB. We are grateful to Ray
Brown for critical reading of the manuscript. Finally, we are indebted
to Rita Rosendahl for excellent technical assistance.
The work was supported in part by grants from the Danish National
Science and Medical Research Councils, The Carlsberg Foundation, Novo
Nordisk Foundation, and Karen Elise Jensen Foundation. H.P., J.N., and
C.K.D. were supported by the University of Aarhus.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Molecular and Structural Biology, University of Aarhus, C. F. Møllers Allé, Building 130, DK-8000 Aarhus C, Denmark. Phone: 45 8942 2686. Fax: 45 8619 6500. E-mail: Kjems{at}biobase.dk.
 |
REFERENCES |
| 1.
|
Askjaer, P.,
A. Bachi,
M. Wilm,
F. R. Bischoff,
D. L. Weeks,
V. Ogniewski,
M. Ohno,
C. Niehrs,
J. Kjems,
I. W. Mattaj, and M. Fornerod.
1999.
RanGTP-regulated interactions of CRM1 with nucleoporins and a shuttling DEAD-box helicase.
Mol. Cell. Biol.
19:6276-6285[Abstract/Free Full Text].
|
| 2.
|
Bass, B. L.
1997.
RNA editing and hypermutation by adenosine deamination.
Trends Biochem. Sci.
22:157-162[CrossRef][Medline].
|
| 3.
|
Begitt, A.,
T. Meyer,
M. van Rossum, and U. Vinkemeier.
2000.
Nucleocytoplasmic translocation of Stat1 is regulated by a leucine-rich export signal in the coiled-coil domain.
Proc. Natl. Acad. Sci. USA
97:10418-10423[Abstract/Free Full Text].
|
| 4.
|
Bischoff, F. R., and D. Görlich.
1997.
RanBP1 is crucial for the release of RanGTP from importin beta-related nuclear transport factors.
FEBS Lett.
419:249-254[CrossRef][Medline].
|
| 5.
|
Brown, B. A.,
K. Lowenhaupt,
C. M. Wilbert,
E. B. Hanlon, and A. Rich.
2000.
The Z domain of the editing enzyme dsRNA adenosine deaminase binds left-handed Z-RNA as well as Z-DNA.
Proc. Natl. Acad. Sci. USA
97:13532-13536[Abstract/Free Full Text].
|
| 6.
|
Burns, C. M.,
H. Chu,
S. M. Rueter,
L. K. Hutchinson,
H. Canton,
E. Sanders-Bush, and R. B. Emeson.
1997.
Regulation of serotonin-2C receptor G-protein coupling by RNA editing.
Nature
387:303-308[CrossRef][Medline].
|
| 7.
|
Cattaneo, R.
1994.
Biased (A I) hypermutation of animal RNA virus genomes.
Curr. Opin. Genet. Dev.
4:895-900[CrossRef][Medline].
|
| 8.
|
Dabiri, G. A.,
F. Lai,
R. A. Drakas, and K. Nishikura.
1996.
Editing of the GluR-B ion channel RNA in vitro by recombinant double-stranded RNA adenosine deaminase.
EMBO J.
15:34-45[Medline].
|
| 9.
|
Der, S. D.,
A. Zhou,
B. R. Williams, and R. H. Silverman.
1998.
Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays.
Proc. Natl. Acad. Sci. USA
95:15623-15628[Abstract/Free Full Text].
|
| 10.
|
Eckmann, C. R., and M. F. Jantsch.
1999.
The RNA-editing enzyme ADAR1 is localized to the nascent ribonucleoprotein matrix on Xenopus lampbrush chromosomes but specifically associates with an atypical loop.
J. Cell Biol.
144:603-615[Abstract/Free Full Text].
|
| 11.
|
Egebjerg, J.,
V. Kukekov, and S. F. Heinemann.
1994.
Intron sequence directs RNA editing of the glutamate receptor subunit GluR2 coding sequence.
Proc. Natl. Acad. Sci. USA
91:10270-10274[Abstract/Free Full Text].
|
| 12.
|
Fischer, U.,
J. Huber,
W. C. Boelens,
I. W. Mattaj, and R. Luhrmann.
1995.
The HIV-1 Rev activation domain is a nuclear export signal that accesses an export pathway used by specific cellular RNAs.
Cell
82:475-483[CrossRef][Medline].
|
| 13.
|
Fornerod, M.,
M. Ohno,
M. Yoshida, and I. W. Mattaj.
1997.
CRM1 is an export receptor for leucine-rich nuclear export signals.
Cell
90:1051-1060[CrossRef][Medline].
|
| 14.
|
Fukuda, M.,
S. Asano,
T. Nakamura,
M. Adachi,
M. Yoshida,
M. Yanagida, and E. Nishida.
1997.
CRM1 is responsible for intracellular transport mediated by the nuclear export signal.
Nature
390:308-311[CrossRef][Medline].
|
| 15.
|
George, C. X., and C. E. Samuel.
1999.
Human RNA-specific adenosine deaminase ADAR1 transcripts possess alternative exon 1 structures that initiate from different promoters, one constitutively active and the other interferon inducible.
Proc. Natl. Acad. Sci. USA
96:4621-4626[Abstract/Free Full Text].
|
| 16.
|
Görlich, D., and U. Kutay.
1999.
Transport between the cell nucleus and the cytoplasm.
Annu. Rev. Cell Dev. Biol.
15:607-660[CrossRef][Medline].
|
| 17.
|
Görlich, D.,
N. Pante,
U. Kutay,
U. Aebi, and F. R. Bischoff.
1996.
Identification of different roles for RanGDP and RanGTP in nuclear protein import.
EMBO J.
15:5584-5594[Medline].
|
| 18.
|
Hanrahan, C. J.,
M. J. Palladino,
B. Ganetzky, and R. A. Reenan.
2000.
RNA editing of the Drosophila para Na(+) channel transcript. Evolutionary conservation and developmental regulation.
Genetics
155:1149-1160[Abstract/Free Full Text].
|
| 19.
|
Herbert, A.,
J. Alfken,
Y. G. Kim,
I. S. Mian,
K. Nishikura, and A. Rich.
1997.
A Z-DNA binding domain present in the human editing enzyme, double-stranded RNA adenosine deaminase.
Proc. Natl. Acad. Sci. USA
94:8421-8426[Abstract/Free Full Text].
|
| 20.
|
Higuchi, M.,
S. Maas,
F. N. Single,
J. Hartner,
A. Rozov,
N. Burnashev,
D. Feldmeyer,
R. Sprengel, and P. H. Seeburg.
2000.
Point mutation in an AMPA receptor gene rescues lethality in mice deficient in the RNA-editing enzyme ADAR2.
Nature
406:78-81[CrossRef][Medline].
|
| 21.
|
Higuchi, M.,
F. N. Single,
M. Kohler,
B. Sommer,
R. Sprengel, and P. H. Seeburg.
1993.
RNA editing of AMPA receptor subunit GluR-B: a base-paired intron-exon structure determines position and efficiency.
Cell
75:1361-1370[CrossRef][Medline].
|
| 22.
|
Hough, R. F., and B. L. Bass.
1997.
Analysis of Xenopus dsRNA adenosine deaminase cDNAs reveals similarities to DNA methyltransferases.
RNA
3:356-370[Abstract].
|
| 23.
|
Hurst, S. R.,
R. F. Hough,
P. J. Aruscavage, and B. L. Bass.
1995.
Deamination of mammalian glutamate receptor RNA by Xenopus dsRNA adenosine deaminase: similarities to in vivo RNA editing.
RNA
1:1051-1060[Abstract].
|
| 24.
|
Huxford, T.,
D. B. Huang,
S. Malek, and G. Ghosh.
1998.
The crystal structure of the I B /NF- B complex reveals mechanisms of NF- B inactivation.
Cell
95:759-770[CrossRef][Medline].
|
| 25.
|
Jacobs, M. D., and S. C. Harrison.
1998.
Structure of an I B /NF- B complex.
Cell
95:749-758[CrossRef][Medline].
|
| 26.
|
Jeffrey, P. D.,
S. Gorina, and N. P. Pavletich.
1995.
Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms.
Science
267:1498-1502[Abstract/Free Full Text].
|
| 27.
|
Ke, S. H., and E. L. Madison.
1997.
Rapid and efficient site-directed mutagenesis by single-tube `megaprimer' PCR method.
Nucleic Acids Res.
25:3371-3372[Abstract/Free Full Text].
|
| 28.
|
Kehlenbach, R. H.,
A. Dickmanns,
A. Kehlenbach,
T. Guan, and L. Gerace.
1999.
A role for RanBP1 in the release of CRM1 from the nuclear pore complex in a terminal step of nuclear export.
J. Cell Biol.
145:645-657[Abstract/Free Full Text].
|
| 29.
|
Keller, W.,
J. Wolf, and A. Gerber.
1999.
Editing of messenger RNA precursors and of tRNAs by adenosine to inosine conversion.
FEBS Lett.
452:71-76[CrossRef][Medline].
|
| 30.
|
Kim, U.,
T. L. Garner,
T. Sanford,
D. Speicher,
J. M. Murray, and K. Nishikura.
1994.
Purification and characterization of double-stranded RNA adenosine deaminase from bovine nuclear extracts.
J. Biol. Chem.
269:13480-13489[Abstract/Free Full Text].
|
| 31.
|
Kim, U.,
Y. Wang,
T. Sanford,
Y. Zeng, and K. Nishikura.
1994.
Molecular cloning of cDNA for double-stranded RNA adenosine deaminase, a candidate enzyme for nuclear RNA editing.
Proc. Natl. Acad. Sci. USA
91:11457-11461[Abstract/Free Full Text].
|
| 32.
|
Kohler, M.,
N. Burnashev,
B. Sakmann, and P. H. Seeburg.
1993.
Determinants of Ca2+ permeability in both TM1 and TM2 of high affinity kainate receptor channels: diversity by RNA editing.
Neuron
10:491-500[CrossRef][Medline].
|
| 33.
|
Kudo, N.,
N. Matsumori,
H. Taoka,
D. Fujiwara,
E. P. Schreiner,
B. Wolff,
M. Yoshida, and S. Horinouchi.
1999.
Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a cysteine residue in the central conserved region.
Proc. Natl. Acad. Sci. USA
96:9112-9117[Abstract/Free Full Text].
|
| 34.
|
Lai, F.,
C. X. Chen,
K. C. Carter, and K. Nishikura.
1997.
Editing of glutamate receptor B subunit ion channel RNAs by four alternatively spliced DRADA2 double-stranded RNA adenosine deaminases.
Mol. Cell. Biol.
17:2413-2424[Abstract].
|
| 35.
|
Liu, Y.,
R. B. Emeson, and C. E. Samuel.
1999.
Serotonin-2C receptor pre-mRNA editing in rat brain and in vitro by splice site variants of the interferon-inducible double-stranded RNA-specific adenosine deaminase ADAR1.
J. Biol. Chem.
274:18351-18358[Abstract/Free Full Text].
|
| 36.
|
Liu, Y.,
C. X. George,
J. B. Patterson, and C. E. Samuel.
1997.
Functionally distinct double-stranded RNA-binding domains associated with alternative splice site variants of the interferon-inducible double-stranded RNA-specific adenosine deaminase.
J. Biol. Chem.
272:4419-4428[Abstract/Free Full Text].
|
| 37.
|
Liu, Y., and C. E. Samuel.
1999.
Editing of glutamate receptor subunit B pre-mRNA by splice-site variants of interferon-inducible double-stranded RNA-specific adenosine deaminase ADAR1.
J. Biol. Chem.
274:5070-5077[Abstract/Free Full Text].
|
| 38.
|
Lomeli, H.,
J. Mosbacher,
T. Melcher,
T. Hoger,
J. R. Geiger,
T. Kuner,
H. Monyer,
M. Higuchi,
A. Bach, and P. H. Seeburg.
1994.
Control of kinetic properties of AMPA receptor channels by nuclear RNA editing.
Science
266:1709-1713[Abstract/Free Full Text].
|
| 39.
|
Maas, S.,
T. Melcher,
A. Herb,
P. H. Seeburg,
W. Keller,
S. Krause,
M. Higuchi, and M. A. O'Connell.
1996.
Structural requirements for RNA editing in glutamate receptor pre-mRNAs by recombinant double-stranded RNA adenosine deaminase.
J. Biol. Chem.
271:12221-12226[Abstract/Free Full Text].
|
| 40.
|
Mattaj, I. W., and L. Englmeier.
1998.
Nucleocytoplasmic transport: the soluble phase.
Annu. Rev. Biochem.
67:265-306[CrossRef][Medline].
|
| 41.
|
Melcher, T.,
S. Maas,
A. Herb,
R. Sprengel,
P. H. Seeburg, and M. Higuchi.
1996.
A mammalian RNA editing enzyme.
Nature
379:460-464[CrossRef][Medline].
|
| 42.
|
Michael, W. M.,
M. Choi, and G. Dreyfuss.
1995.
A nuclear export signal in hnRNP A1: a signal-mediated, temperature-dependent nuclear protein export pathway.
Cell
83:415-422[CrossRef][Medline].
|
| 43.
|
Mittl, P. R.,
P. Chene, and M. G. Grutter.
1998.
Crystallization and structure solution of p53 (residues 326-356) by molecular replacement using an NMR model as template.
Acta Crystallogr. D.
54(Pt. 1):86-89[CrossRef][Medline].
|
| 44.
|
Nilsson, J.,
P. Askjaer, and J. Kjems.
2001.
A role for the basic patch and the C terminus of RanGTP in regulating the dynamic interactions with importin beta, CRM1 and RanBP1.
J. Mol. Biol.
305:231-243[CrossRef][Medline].
|
| 45.
|
O'Connell, M. A.,
A. Gerber, and W. Keller.
1997.
Purification of human double-stranded RNA-specific editase 1 (hRED1) involved in editing of brain glutamate receptor B pre-mRNA.
J. Biol. Chem.
272:473-478[Abstract/Free Full Text].
|
| 46.
|
O'Connell, M. A.,
S. Krause,
M. Higuchi,
J. J. Hsuan,
N. F. Totty,
A. Jenny, and W. Keller.
1995.
Cloning of cDNAs encoding mammalian double-stranded RNA-specific adenosine deaminase.
Mol. Cell. Biol.
15:1389-1397[Abstract].
|
| 47.
|
Ossareh-Nazari, B.,
F. Bachelerie, and C. Dargemont.
1997.
Evidence for a role of CRM1 in signal-mediated nuclear protein export.
Science
278:141-144[Abstract/Free Full Text].
|
| 48.
|
Patterson, J. B., and C. E. Samuel.
1995.
Expression and regulation by interferon of a double-stranded-RNA-specific adenosine deaminase from human cells: evidence for two forms of the deaminase.
Mol. Cell. Biol.
15:5376-5388[Abstract].
|
| 49.
|
Patton, D. E.,
T. Silva, and F. Bezanilla.
1997.
RNA editing generates a diverse array of transcripts encoding squid Kv2 K+ channels with altered functional properties.
Neuron
19:711-722[CrossRef][Medline].
|
| 50.
|
Rexach, M., and G. Blobel.
1995.
Protein import into nuclei: association and dissociation reactions involving transport substrate, transport factors, and nucleoporins.
Cell
83:683-692[CrossRef][Medline].
|
| 51.
|
Rittinger, K.,
J. Budman,
J. Xu,
S. Volinia,
L. C. Cantley,
S. J. Smerdon,
S. J. Gamblin, and M. B. Yaffe.
1999.
Structural analysis of 14-3-3 phosphopeptide complexes identifies a dual role for the nuclear export signal of 14-3-3 in ligand binding.
Mol. Cell
4:153-166[CrossRef][Medline].
|
| 52.
|
Rueter, S. M.,
T. R. Dawson, and R. B. Emeson.
1999.
Regulation of alternative splicing by RNA editing.
Nature
399:75-80[CrossRef][Medline].
|
| 53.
|
Schade, M.,
C. J. Turner,
K. Lowenhaupt,
A. Rich, and A. Herbert.
1999.
Structure-function analysis of the Z-DNA-binding domain Z- of dsRNA adenosine deaminase type I reveals similarity to the (alpha + beta) family of helix-turn-helix proteins.
EMBO J.
18:470-479[CrossRef][Medline].
|
| 54.
|
Schwartz, T.,
M. A. Rould,
K. Lowenhaupt,
A. Herbert, and A. Rich.
1999.
Crystal structure of the Z- domain of the human editing enzyme ADAR1 bound to left-handed Z-DNA.
Science
284:1841-1845[Abstract/Free Full Text].
|
| 55.
|
Semenov, E. P., and W. L. Pak.
1999.
Diversification of Drosophila chloride channel gene by multiple posttranscriptional mRNA modifications.
J. Neurochem.
72:66-72[CrossRef][Medline].
|
| 56.
|
Slavov, D.,
T. Crnogorac-Jurcevic,
M. Clark, and K. Gardiner.
2000.
Comparative analysis of the DRADA A-to-I RNA editing gene from mammals, pufferfish and zebrafish.
Gene
250:53-60[CrossRef][Medline].
|
| 57.
|
Smith, L. A.,
A. A. Peixoto, and J. C. Hall.
1998.
RNA editing in the Drosophila DMCA1A calcium-channel alpha 1 subunit transcript.
J. Neurogenet.
12:227-240[Medline].
|
| 58.
|
Stade, K.,
C. S. Ford,
C. Guthrie, and K. Weis.
1997.
Exportin 1 (Crm1p) is an essential nuclear export factor.
Cell
90:1041-1050[CrossRef][Medline].
|
| 59.
|
Wagner, R. W.,
C. Yoo,
L. Wrabetz,
J. Kamholz,
J. Buchhalter,
N. F. Hassan,
K. Khalili,
S. U. Kim,
B. Perussia,
F. A. McMorris, and K. Nishikura.
1990.
Double-stranded RNA unwinding and modifying activity is detected ubiquitously in primary tissues and cell lines.
Mol. Cell. Biol.
10:5586-5590[Abstract/Free Full Text].
|
| 60.
|
Wang, Q.,
J. Khillan,
P. Gadue, and K. Nishikura.
2000.
Requirement of the RNA editing deaminase ADAR1 gene for embryonic erythropoiesis.
Science
290:1765-1768[Abstract/Free Full Text].
|
| 61.
|
Weis, K.,
C. Dingwall, and A. I. Lamond.
1996.
Characterization of the nuclear protein import mechanism using Ran mutants with altered nucleotide binding specificities.
EMBO J.
15:7120-7128[Medline].
|
| 62.
|
Wen, W.,
J. L. Meinkoth,
R. Y. Tsien, and S. S. Taylor.
1995.
Identification of a signal for rapid export of proteins from the nucleus.
Cell
82:463-473[CrossRef][Medline].
|
| 63.
|
Yang, J.,
E. S. Bardes,
J. D. Moore,
J. Brennan,
M. A. Powers, and S. Kornbluth.
1998.
Control of cyclin B1 localization through regulated binding of the nuclear export factor CRM1.
Genes Dev.
12:2131-2143[Abstract/Free Full Text].
|
| 64.
|
Yang, J. H.,
P. Sklar,
R. Axel, and T. Maniatis.
1997.
Purification and characterization of a human RNA adenosine deaminase for glutamate receptor B pre-mRNA editing.
Proc. Natl. Acad. Sci. USA
94:4354-4359[Abstract/Free Full Text].
|
Molecular and Cellular Biology, November 2001, p. 7862-7871, Vol. 21, No. 22
0270-7306/01/$04.00+0 DOI: 10.1128/MCB.21.22.7862-7871.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Fritz, J., Strehblow, A., Taschner, A., Schopoff, S., Pasierbek, P., Jantsch, M. F.
(2009). RNA-Regulated Interaction of Transportin-1 and Exportin-5 with the Double-Stranded RNA-Binding Domain Regulates Nucleocytoplasmic Shuttling of ADAR1. Mol. Cell. Biol.
29: 1487-1497
[Abstract]
[Full Text]
-
Phuphuakrat, A., Kraiwong, R., Boonarkart, C., Lauhakirti, D., Lee, T.-H., Auewarakul, P.
(2008). Double-Stranded RNA Adenosine Deaminases Enhance Expression of Human Immunodeficiency Virus Type 1 Proteins. J. Virol.
82: 10864-10872
[Abstract]
[Full Text]
-
Gaston, K. W., Rubio, M. A. T., Spears, J. L., Pastar, I., Papavasiliou, F. N., Alfonzo, J. D.
(2007). C to U editing at position 32 of the anticodon loop precedes tRNA 5' leader removal in trypanosomatids. Nucleic Acids Res
35: 6740-6749
[Abstract]
[Full Text]
-
Lykke-Andersen, S., Pinol-Roma, S., Kjems, J.
(2007). Alternative splicing of the ADAR1 transcript in a region that functions either as a 5'-UTR or an ORF. RNA
13: 1732-1744
[Abstract]
[Full Text]
-
Poulsen, H., Jorgensen, R., Heding, A., Nielsen, F. C., Bonven, B., Egebjerg, J.
(2006). Dimerization of ADAR2 is mediated by the double-stranded RNA binding domain. RNA
12: 1350-1360
[Abstract]
[Full Text]
-
Desterro, J. M.P., Keegan, L. P., Jaffray, E., Hay, R. T., O'Connell, M. A., Carmo-Fonseca, M.
(2005). SUMO-1 Modification Alters ADAR1 Editing Activity. Mol. Biol. Cell
16: 5115-5126
[Abstract]
[Full Text]
-
George, C. X., Wagner, M. V., Samuel, C. E.
(2005). Expression of Interferon-inducible RNA Adenosine Deaminase ADAR1 during Pathogen Infection and Mouse Embryo Development Involves Tissue-selective Promoter Utilization and Alternative Splicing. J. Biol. Chem.
280: 15020-15028
[Abstract]
[Full Text]
-
Yang, W., Wang, Q., Howell, K. L., Lee, J. T., Cho, D.-S. C., Murray, J. M., Nishikura, K.
(2005). ADAR1 RNA Deaminase Limits Short Interfering RNA Efficacy in Mammalian Cells. J. Biol. Chem.
280: 3946-3953
[Abstract]
[Full Text]
-
Wang, Q., Carmichael, G. G.
(2004). Effects of Length and Location on the Cellular Response to Double-Stranded RNA. Microbiol. Mol. Biol. Rev.
68: 432-452
[Abstract]
[Full Text]
-
Nie, Y., Zhao, Q., Su, Y., Yang, J.-H.
(2004). Subcellular Distribution of ADAR1 Isoforms Is Synergistically Determined by Three Nuclear Discrimination Signals and a Regulatory Motif. J. Biol. Chem.
279: 13249-13255
[Abstract]
[Full Text]
-
Yang, J.-H., Nie, Y., Zhao, Q., Su, Y., Pypaert, M., Su, H., Rabinovici, R.
(2003). Intracellular Localization of Differentially Regulated RNA-specific Adenosine Deaminase Isoforms in Inflammation. J. Biol. Chem.
278: 45833-45842
[Abstract]
[Full Text]
-
Kim, Y.-G., Muralinath, M., Brandt, T., Pearcy, M., Hauns, K., Lowenhaupt, K., Jacobs, B. L., Rich, A.
(2003). A role for Z-DNA binding in vaccinia virus pathogenesis. Proc. Natl. Acad. Sci. USA
100: 6974-6979
[Abstract]
[Full Text]
-
Cho, D.-S. C., Yang, W., Lee, J. T., Shiekhattar, R., Murray, J. M., Nishikura, K.
(2003). Requirement of Dimerization for RNA Editing Activity of Adenosine Deaminases Acting on RNA. J. Biol. Chem.
278: 17093-17102
[Abstract]
[Full Text]
-
WONG, S. K., SATO, S., LAZINSKI, D. W.
(2003). Elevated activity of the large form of ADAR1 in vivo: Very efficient RNA editing occurs in the cytoplasm. RNA
9: 586-598
[Abstract]
[Full Text]
-
Desterro, J. M. P., Keegan, L. P., Lafarga, M., Berciano, M. T., O'Connell, M., Carmo-Fonseca, M.
(2003). Dynamic association of RNA-editing enzymes with the nucleolus. J. Cell Sci.
116: 1805-1818
[Abstract]
[Full Text]
-
Maas, S., Rich, A., Nishikura, K.
(2003). A-to-I RNA Editing: Recent News and Residual Mysteries. J. Biol. Chem.
278: 1391-1394
[Full Text]
-
Wong, S. K., Lazinski, D. W.
(2002). Replicating hepatitis delta virus RNA is edited in the nucleus by the small form of ADAR1. Proc. Natl. Acad. Sci. USA
99: 15118-15123
[Abstract]
[Full Text]
-
Strehblow, A., Hallegger, M., Jantsch, M. F.
(2002). Nucleocytoplasmic Distribution of Human RNA-editing Enzyme ADAR1 Is Modulated by Double-stranded RNA-binding Domains, a Leucine-rich Export Signal, and a Putative Dimerization Domain. Mol. Biol. Cell
13: 3822-3835
[Abstract]
[Full Text]